# reload+after+2024-01-20 12:45:06.573876
address1§Avinguda de la Generalitat, 152
address2§Parc de Negocis Can Sant Joan Sant Cugat del Valles
city§Barcelona
zip§08174
country§Spain
phone§34 93 571 05 00
fax§34 93 800 80 00
website§https://www.grifols.com
industry§Drug Manufacturers—General
sector§Healthcare
longBusinessSummary§Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
fullTimeEmployees§24000
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Thomas H. Glanzmann', 'age': 65, 'title': 'CEO & Executive Chairman', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 164340, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Raimon  Grifols Roura', 'age': 59, 'title': 'Chief Corporate Officer & Vice-Chairman', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 1139424, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Víctor  Grifols Deu', 'age': 46, 'title': 'COO & Director', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 1139424, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alfredo Arroyo Guerra', 'age': 65, 'title': 'CFO & VP', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mrs. Eva  Bastida Tubau', 'title': 'Corporate Vice President and Director of Scientific & Medical Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Nuria Pascual Lapeña', 'age': 59, 'title': 'VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David Ian Bell', 'age': 69, 'title': 'Chief Corporate Development, Legal & Data Protection Officer', 'yearBorn': 1954, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Maria  Teresa-Rioné Llano', 'age': 58, 'title': 'Chief Communications Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Montserrat Gaja Llamas', 'age': 58, 'title': 'Chief Human Resources Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Vicente  Blanquer Torre', 'age': 62, 'title': 'Chief Quality Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§5
compensationRisk§3
shareHolderRightsRisk§10
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
exDividendDate§1622678400
payoutRatio§0.0
fiveYearAvgDividendYield§2.4
beta§0.669
priceToSalesTrailing12Months§1.4681752
currency§USD
dateShortInterest§1702598400
forwardEps§1.06
pegRatio§0.5
exchange§NMS
quoteType§EQUITY
shortName§Grifols, S.A.
longName§Grifols, S.A.
firstTradeDateEpochUtc§1307021400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ff4804c3-7e74-32e2-af9a-01ef612b3fc8
gmtOffSetMilliseconds§-18000000
targetHighPrice§17.55
targetLowPrice§15.05
targetMeanPrice§16.3
targetMedianPrice§16.3
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§0.688
grossMargins§0.36776
ebitdaMargins§0.14974
trailingPegRatio§0.4213
